Lisa Miller Sells 47,912 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) COO Lisa Miller sold 47,912 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the completion of the sale, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $12.22 on Friday. The company has a 50-day simple moving average of $10.29 and a two-hundred day simple moving average of $8.19. LifeStance Health Group, Inc. has a 12-month low of $4.77 and a 12-month high of $12.43. The firm has a market cap of $4.74 billion, a price-to-earnings ratio of 94.01 and a beta of 1.14. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company’s quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.01) earnings per share. On average, equities analysts forecast that LifeStance Health Group, Inc. will post 0.15 EPS for the current year.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Analyst support remains favorable. Morgan Stanley reaffirmed its Buy rating on LFST, adding to a broader consensus view that includes six Buy ratings and an overall “Moderate Buy” recommendation. Morgan Stanley Reaffirms Buy Rating
• Positive Sentiment: Recent fundamentals are improving. LifeStance’s latest quarterly results exceeded analyst expectations, with earnings of $0.06 per share versus a $0.03 consensus estimate and revenue of $435.35 million versus expectations of $414.58 million. Revenue increased 26.1% year over year, supporting the stock’s momentum-investor appeal. LifeStance Weekly Momentum Analysis
• Positive Sentiment: Market momentum remains strong. LFST recently set a new 52-week high following an analyst upgrade, signaling continued investor optimism. However, the stock’s elevated price-to-earnings ratio of roughly 94 means future appreciation likely depends on sustained earnings growth. LifeStance Sets New 52-Week High
• Neutral Sentiment: Zacks highlighted LFST among low-leverage stocks that may appeal to investors seeking companies with resilient balance sheets amid market volatility. LifeStance’s debt-to-equity ratio is 0.18, but the article does not represent a material change to company guidance. Zacks Low-Leverage Stocks Article
• Negative Sentiment: Multiple insiders sold shares. Major shareholder TPG GP A sold 13.64 million shares for approximately $144.9 million. Separately, COO Lisa K. Miller sold about $519,845 of stock and CTO Vukasin Paunovich sold about $481,675. Each retained a sizable position, but the transactions could create concerns about profit-taking and near-term selling pressure. LifeStance Insider Sale Filing

Wall Street Analysts Forecast Growth

Several analysts have weighed in on LFST shares. JPMorgan Chase & Co. increased their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lifted their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday. BTIG Research upped their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Barclays increased their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.62.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Assetmark Inc. grew its position in shares of LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after buying an additional 1,367 shares during the last quarter. California State Teachers Retirement System lifted its stake in LifeStance Health Group by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock worth $885,000 after acquiring an additional 1,966 shares during the period. Vident Advisory LLC lifted its stake in LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock worth $112,000 after acquiring an additional 2,447 shares during the period. Xponance LLC boosted its holdings in LifeStance Health Group by 26.4% in the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after acquiring an additional 2,745 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in LifeStance Health Group by 14.8% in the first quarter. Diversified Trust Co now owns 21,532 shares of the company’s stock valued at $137,000 after acquiring an additional 2,770 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.